These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21812508)

  • 1. Romidepsin: in the treatment of T-cell lymphoma.
    Yang LP
    Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
    Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.
    Lyseng-Williamson KA; Yang LP
    Am J Clin Dermatol; 2012 Feb; 13(1):67-71. PubMed ID: 22066664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
    Piekarz RL; Frye R; Turner M; Wright JJ; Allen SL; Kirschbaum MH; Zain J; Prince HM; Leonard JP; Geskin LJ; Reeder C; Joske D; Figg WD; Gardner ER; Steinberg SM; Jaffe ES; Stetler-Stevenson M; Lade S; Fojo AT; Bates SE
    J Clin Oncol; 2009 Nov; 27(32):5410-7. PubMed ID: 19826128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romidepsin for cutaneous T-cell lymphoma.
    Prince HM; Dickinson M
    Clin Cancer Res; 2012 Jul; 18(13):3509-15. PubMed ID: 22535155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
    Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE
    Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Romidepsin (Istodax
    Ro T; Nakayama N; Achiwa H; Ohtsu T
    Nihon Yakurigaku Zasshi; 2018; 151(3):122-129. PubMed ID: 29526921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
    Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
    J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romidepsin for the treatment of T-cell lymphomas.
    McGraw AL
    Am J Health Syst Pharm; 2013 Jul; 70(13):1115-22. PubMed ID: 23784158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
    Jain N; Odenike O
    Expert Opin Pharmacother; 2010 Dec; 11(18):3073-84. PubMed ID: 21080855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery and development of romidepsin for the treatment of T-cell lymphoma.
    Smolewski P; Robak T
    Expert Opin Drug Discov; 2017 Aug; 12(8):859-873. PubMed ID: 28641053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
    J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
    Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
    Bates SE; Eisch R; Ling A; Rosing D; Turner M; Pittaluga S; Prince HM; Kirschbaum MH; Allen SL; Zain J; Geskin LJ; Joske D; Popplewell L; Cowen EW; Jaffe ES; Nichols J; Kennedy S; Steinberg SM; Liewehr DJ; Showe LC; Steakley C; Wright J; Fojo T; Litman T; Piekarz RL
    Br J Haematol; 2015 Jul; 170(1):96-109. PubMed ID: 25891346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Borchmann P; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan S; Shustov A; Nichols J; Carroll S; Balser J; Balser B; Horwitz S
    J Clin Oncol; 2012 Feb; 30(6):631-6. PubMed ID: 22271479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
    Falchi L; Ma H; Klein S; Lue JK; Montanari F; Marchi E; Deng C; Kim HA; Rada A; Jacob AT; Kinahan C; Francescone MM; Soderquist CR; Park DC; Bhagat G; Nandakumar R; Menezes D; Scotto L; Sokol L; Shustov AR; O'Connor OA
    Blood; 2021 Apr; 137(16):2161-2170. PubMed ID: 33171487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.
    Shustov A; Coiffier B; Horwitz S; Sokol L; Pro B; Wolfson J; Balser B; Eisch R; Popplewell L; Prince HM; Allen SL; Piekarz R; Bates S
    Leuk Lymphoma; 2017 Oct; 58(10):2335-2341. PubMed ID: 28264616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
    Noonan AM; Eisch RA; Liewehr DJ; Sissung TM; Venzon DJ; Flagg TP; Haigney MC; Steinberg SM; Figg WD; Piekarz RL; Bates SE
    Clin Cancer Res; 2013 Jun; 19(11):3095-104. PubMed ID: 23589175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.